{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:07:00Z","timestamp":1789913220682,"version":"4.0.1"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tofacitinib is an oral Janus kinase inhibitor. These post\u2010hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52\u2010week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo\u2010treated patients advanced to tofacitinib at week 16. Primary efficacy end\u2010points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\u201075) and Physician's Global Assessment (<jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content>) of \u201cclear\u201d or \u201calmost clear\u201d (<jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content> response) at week 16. Other end\u2010points included: Itch Severity Item (<jats:styled-content style=\"fixed-case\">ISI<\/jats:styled-content>), Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>) score and Nail Psoriasis Severity Index (<jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>). Adverse events (AEs) were recorded throughout the study. Overall, 58 Japanese patients were included in this analysis (tofacitinib 5 mg b.i.d., <jats:italic>n<\/jats:italic> = 22; 10 mg b.i.d., <jats:italic>n<\/jats:italic> = 24; placebo, <jats:italic>n<\/jats:italic> = 12); 29 completed the study. At week 16, significantly more patients receiving tofacitinib 5 and 10 mg <jats:styled-content style=\"fixed-case\">b.i.d.<\/jats:styled-content> versus placebo achieved <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\u201075 (50% and 75% vs 0%, <jats:italic>P<\/jats:italic> &lt; 0.01) and <jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content> response (59% and 75% vs 0%, <jats:italic>P<\/jats:italic> &lt; 0.001). Substantial improvements in <jats:styled-content style=\"fixed-case\">ISI<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> DLQI<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content> score were observed with both tofacitinib doses. Over 52 weeks, similar rates of AEs were reported across treatment groups; one serious <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> occurred with tofacitinib 10 mg b.i.d. Herpes zoster occurred in three patients receiving tofacitinib 10 mg b.i.d. No deaths, serious infections, malignancies or gastrointestinal perforations were reported. Results were generally consistent with global analysis, suggesting sustained efficacy and a manageable safety profile, with increased herpes zoster incidence, of tofacitinib in Japanese patients with psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.13956","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T05:46:48Z","timestamp":1500270408000},"page":"1228-1237","source":"Crossref","is-referenced-by-count":25,"title":["Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo\u2010controlled phase 3 trial"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8863-9428","authenticated-orcid":false,"given":"Masatoshi","family":"Abe","sequence":"first","affiliation":[{"name":"Sapporo Skin Clinic Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-2849","authenticated-orcid":false,"given":"Chikako","family":"Nishigori","sequence":"additional","affiliation":[{"name":"Division of Dermatology Kobe University Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Torii","sequence":"additional","affiliation":[{"name":"Division of Dermatology Tokyo Yamate Medical Center Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Ihn","sequence":"additional","affiliation":[{"name":"Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ito","sequence":"additional","affiliation":[{"name":"JR Sapporo Hospital Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Isogawa","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tomochika","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research and K. Papp Clinical Research Inc. Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp567"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125476"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02636.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.046"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3208023523","article-title":"Social impact of the burden of psoriasis: effects on patients and practice","volume":"20","author":"Feldman SR","year":"2014","journal-title":"Dermatol Online J"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.508"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12239"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0634-8"},{"key":"e_1_2_7_13_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Report on the Deliberation Results \u2010 Cosentyx. [Cited 17 Jan 2017] Available from URL:http:\/\/www.pmda.go.jp\/files\/000210413.pdf#page=33. Last updated 2014."},{"key":"e_1_2_7_14_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Approved products list (new drug: 5\/2016). [Cited 21 Dec 2016] Available from URL:https:\/\/www.pmda.go.jp\/files\/000215608.pdf. Last updated 2016."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12745"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12372"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_2_7_34_1","first-page":"S1","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate\u2010to\u2010severe ulcerative colitis: results from 2 phase 3 randomised controlled trials","volume":"10","author":"Sandborn WJ","year":"2016","journal-title":"J Crohns Colitis"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13702"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13258"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00971.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12859"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"key":"e_1_2_7_43_1","article-title":"Herpes zoster and tofacitinib therapy in patients with psoriasis","volume":"135","author":"Valdez H","year":"2015","journal-title":"J Invest Dermatol"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12307"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.4956"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04230.x"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12679"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.07.009"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22628"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw205"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205148"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12370"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:10:12Z","timestamp":1695535812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/1346-8138.13956"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13956","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}